CLINICAL TRIALS PROFILE FOR BIKTARVY

All Clinical Trials for biktarvy

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	Canadian Institutes of Health Research (CIHR)	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	CIHR Canadian HIV Trials Network	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	St. Michael's Hospital, Toronto	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03259698 ↗	Optimizing the Delivery of HIV nPEP	Recruiting	Unity Health Toronto	Phase 2	2021-10-01	Despite decades of traditional prevention efforts based on behavior change and condom use, Ontario has seen over 700 new HIV infections annually over the past 10 years. Post-exposure prophylaxis (PEP) is one such approach, in which uninfected persons use 28 days of antiretroviral medications (ARVs) shortly after an HIV exposure to minimize the risk of acquiring HIV. PEP is highly efficacious, is considered a standard of care intervention based on medical and ethical grounds, and is supported by treatment guidelines. Yet several implementation challenges have limited its clinical and public health impact in Ontario, where no formal PEP policy exists. Our proposal seeks to optimize two aspects of delivering PEP for sexual exposures (nPEP). Results will inform the development of a standardized approach to nPEP both province-wide and elsewhere. Thus study has pragmatic, multicenter randomized controlled trial using a 2x2 factorial design to determine whether the proportion of nPEP patients that successfully complete follow-up: 1. is higher among those receiving mobile phone-based text messaging support than among those receiving standard care; and 2. is non-inferior among those receiving care from a sexual health clinic nurse compared to those receiving hospital-based physician care. The prospective, randomized, non-blinded, 2x2 factorial trial that will enroll 318 study participants in Toronto. In Intervention A, we will randomize half of study participants to a text messaging support service ('WelTel'), in which a trained, community-based counselor provides standardized weekly 'check-in' messages during their 12-week course of PEP follow-up. The other half will receive standard care, which does not include any form of active outreach or reminders outside of scheduled appointments. In Intervention B, we will randomize half of participants to receive nurse-led care for PEP follow-up at a local sexual health clinic; the other half will receive standard care by a hospital-based ID physician. The specific activities for each follow-up visit will be clearly defined in a medical directive. In keeping with Ontario legislation on medical directives, nurses will review cases with their authorizing physician or nurse practitioner on a routine basis.
NCT03499483 ↗	Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)	Recruiting	Fenway Community Health	Phase 4	2019-01-24	Study will evaluate the safety and tolerability of once daily Biktarvy for 28 days for prevention of HIV infection in HIV-1-seronegative adults after high-risk sexual contact. (non-occupational post exposure prophylaxis - nPEP)

Clinical Trial Conditions for biktarvy

Condition Name

Condition Name for biktarvy
Intervention	Trials
HIV-1-infection	13
HIV Infections	7
Human Immunodeficiency Virus	5
HIV	5

Condition MeSH

Condition MeSH for biktarvy
Intervention	Trials
HIV Infections	18
Acquired Immunodeficiency Syndrome	10
Infections	5
Infection	4

Clinical Trial Locations for biktarvy

Trials by Country

Trials by Country for biktarvy
Location	Trials
United States	101
Canada	10
Italy	7
United Kingdom	6
Germany	6

Trials by US State

Trials by US State for biktarvy
Location	Trials
Georgia	7
California	7
Texas	6
New Jersey	6
New York	6

Clinical Trial Progress for biktarvy

Clinical Trial Phase

Clinical Trial Phase for biktarvy
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for biktarvy
Clinical Trial Phase	Trials
Recruiting	17
Not yet recruiting	9
COMPLETED	4

Clinical Trial Sponsors for biktarvy

Sponsor Name

Sponsor Name for biktarvy
Sponsor	Trials
Gilead Sciences	18
ViiV Healthcare	4
Chelsea and Westminster NHS Foundation Trust	3

Sponsor Type

Sponsor Type for biktarvy
Sponsor	Trials
Other	61
Industry	28
U.S. Fed	1

Biktarvy: Clinical Trial Landscape, Market Performance, and Future Projections

Last updated: February 19, 2026

Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide), developed by Gilead Sciences, is a single-tablet regimen (STR) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This analysis provides an overview of its clinical trial status, current market position, and projected future performance.

Current Clinical Trial Landscape for Biktarvy

Biktarvy's clinical development has largely focused on demonstrating its efficacy and safety in various HIV-1 patient populations, including treatment-naïve individuals, those with suppressed viral load on existing regimens, and specific subgroups like individuals with mild-to-moderate renal impairment.

Key Clinical Trial Categories

• Treatment-Naïve HIV-1 Patients: Initial pivotal trials established Biktarvy's non-inferiority to comparator regimens.

  • Study 1490: This Phase 3, randomized, double-blind, active-controlled, non-inferiority study evaluated Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, tenofovir alafenamide 25 mg) versus dolutegravir plus emtricitabine and tenofovir disoproxil fumarate (DTG/FTC/TDF) in HIV-1 infected treatment-naïve adults. The primary endpoint was the proportion of participants with HIV-1 RNA > 50 copies/mL at week 48. Biktarvy achieved a statistically similar rate of virologic suppression [1].
  • Study 1474: A similar Phase 3 study, comparing Biktarvy to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF), also demonstrated non-inferiority in virologic suppression at week 48 [1].

• Virologically Suppressed Patients: Trials have investigated switching to Biktarvy from other established regimens.

  • Study 4020: This Phase 3, randomized, double-blind, active-controlled, non-inferiority study assessed switching to Biktarvy from a baseline regimen of DTG/ABC/3TC (dolutegravir/abacavir/lamivudine) in virologically suppressed adults. The study demonstrated non-inferiority of Biktarvy in maintaining viral suppression at week 48 [1].
  • Study 4021: A parallel study evaluated switching to Biktarvy from other specified baseline regimens in virologically suppressed adults, also confirming non-inferiority [1].

• Specific Patient Subgroups:

  • Mild-to-Moderate Renal Impairment: Biktarvy has been studied and approved for use in individuals with creatinine clearance (CrCl) ≥ 30 mL/min.
    • Study 1173: This single-arm, open-label, Phase 2 study evaluated Biktarvy in HIV-1 infected adults with mild (CrCl 60-89 mL/min) or moderate (CrCl 30-59 mL/min) renal impairment. The study demonstrated that Biktarvy effectively suppressed viral load without the need for dose adjustment and was generally well-tolerated [2].

• Long-Term Extension Studies: Ongoing extension studies (e.g., Study 1490 Extension, Study 4020 Extension) are collecting data on the long-term safety and efficacy of Biktarvy, with many participants continuing treatment for several years. These studies track viral load, CD4 count, adverse events, and adherence [1].

• Real-World Evidence Studies: Numerous observational studies and registries are collecting real-world data on Biktarvy's effectiveness and safety in diverse patient populations. These studies contribute to understanding its performance outside of controlled trial settings.

Market Analysis of Biktarvy

Biktarvy has achieved a dominant position in the global HIV treatment market due to its favorable efficacy, safety profile, and convenient single-tablet formulation. Its market penetration is supported by its inclusion in major treatment guidelines and formularies.

Market Share and Sales Performance

• Revenue Growth: Gilead Sciences has reported consistent strong revenue growth for Biktarvy since its launch. In 2022, Biktarvy generated approximately $9.7 billion in sales, representing a 24% increase from 2021 [3]. This trend has continued into 2023, with first-half 2023 sales reaching approximately $5.2 billion [4].
• Market Leadership: Biktarvy is a leading HIV treatment option in both the US and Europe. Its market share in the treatment-naïve segment is particularly high, driven by its efficacy and tolerability.
• Competitive Landscape: Biktarvy competes with other STRs and multi-tablet regimens. Key competitors include:
  • Triumeq (abacavir, dolutegravir, lamivudine) by ViiV Healthcare: Another widely prescribed STR, particularly in treatment-naïve populations.
  • Descovy (emtricitabine, tenofovir alafenamide) + Tivicay (dolutegravir) by Gilead Sciences: A two-drug regimen often used as an alternative.
  • Jardiance (empagliflozin) for HIV co-infections/cardiovascular risk: While not a direct HIV treatment, its use in managing comorbidities in HIV patients can indirectly impact treatment decisions.
  • Long-acting injectables (e.g., Cabotegravir/Rilpiverine by ViiV Healthcare): Representing a newer therapeutic modality.

Key Market Drivers

• High Efficacy and Safety: Biktarvy demonstrates rapid viral suppression and a low incidence of treatment-emergent resistance. Its safety profile is generally favorable, with fewer gastrointestinal side effects compared to older tenofovir formulations.
• Convenience of Single-Tablet Regimen: The once-daily STR format improves patient adherence and quality of life.
• Broad Patient Population Applicability: Its approval across various patient groups, including those with mild-to-moderate renal impairment, expands its use.
• Physician Prescribing Habits: Positive clinical trial data and real-world experience have led to widespread physician adoption.
• Formulary Access and Reimbursement: Biktarvy generally enjoys broad access on insurance formularies, facilitating its uptake.

Challenges and Threats

• Emergence of Long-Acting Injectables: The development of long-acting injectable HIV therapies offers an alternative for patients seeking to avoid daily oral medications.
• Biosimilar Competition: While currently not a significant factor for complex STRs, potential future development of generics for individual components or novel biosimil approaches could emerge.
• Pricing Pressures: Healthcare systems are increasingly focused on cost containment, which could lead to pricing negotiations and market access challenges.
• Evolving Treatment Paradigms: Ongoing research into novel HIV treatment strategies, including therapeutic vaccines and cure research, could alter the long-term treatment landscape.

Future Projections for Biktarvy

The future outlook for Biktarvy remains strong, with continued market growth anticipated in the medium term, though potential shifts are expected beyond this period.

Projected Market Growth

• Continued Dominance: Biktarvy is projected to maintain its leadership position in the global HIV treatment market for at least the next five years. Analysts anticipate continued single-digit to low-double-digit annual growth through 2027-2028, driven by ongoing demand and new patient initiations.
• US and Developed Markets: The US market will continue to be the largest contributor, followed by Europe. Growth in these regions will be steady, driven by switching from older regimens and new diagnoses.
• Emerging Markets: While Biktarvy is available in many emerging markets, its uptake can be slower due to pricing sensitivities and local treatment guidelines. However, as healthcare infrastructure improves and affordability increases, these regions represent significant future growth opportunities.
• Revenue Forecasts: Consensus analyst forecasts project Biktarvy sales to exceed $11 billion by 2025 [5]. Specific projections vary, but the general trend indicates sustained market strength.

Potential Market Evolution and Risks

• Long-Term Competition: The market share of Biktarvy may gradually erode beyond 2028 as newer therapeutic modalities, particularly long-acting injectables and potentially simplified regimens, gain more traction and market penetration.
• Patent Expirations and Generic Entry: While the primary patents for Biktarvy's components are robust, the timeline for potential generic entry for the combination STR will be critical. The exact timing of patent expiries for the full STR formulation will dictate when generic competition can significantly impact market share. This is a key factor to monitor for long-term revenue projections.
• Gilead's R&D Pipeline: Gilead's continued investment in HIV research, including potential next-generation STRs or novel therapeutic approaches, will influence Biktarvy's lifecycle management and future product cannibalization or complementarity.
• Regulatory Landscape: Changes in regulatory approvals for new HIV treatments or evolving treatment guidelines could impact Biktarvy's market position.

Strategic Considerations for Stakeholders

• For Gilead: Continued focus on demonstrating long-term safety and efficacy through real-world data and post-marketing studies is crucial. Exploring new indications or patient populations, if scientifically supported, could extend its lifecycle. Strategic partnerships for broader market access in emerging economies will be important.
• For Investors: Monitor patent expiry timelines for Biktarvy and its key components. Track the competitive landscape, particularly the progress and adoption rates of long-acting injectables and novel therapeutic strategies. Evaluate Gilead's R&D pipeline for future HIV treatments.
• For Healthcare Providers: Staying abreast of evolving treatment guidelines, patient preferences for adherence (oral vs. injectable), and emerging safety data for all available HIV regimens will be critical for optimal patient care.

Key Takeaways

• Biktarvy has established a robust clinical profile through extensive Phase 3 trials demonstrating high efficacy and favorable safety in diverse HIV-1 patient populations.
• The drug is a market leader in HIV treatment, driven by its single-tablet regimen convenience, strong efficacy, and broad physician adoption, generating significant revenue for Gilead Sciences.
• Market projections indicate continued strong sales performance for Biktarvy through at least 2027-2028.
• Long-term market sustainability will be influenced by the increasing adoption of long-acting injectables and the eventual impact of patent expirations and potential generic competition.

Frequently Asked Questions

1. What are the primary endpoints of the pivotal Phase 3 trials for Biktarvy? The primary endpoints of the pivotal Phase 3 trials (e.g., Study 1490, Study 1474) for Biktarvy were the proportion of participants with HIV-1 RNA > 50 copies/mL at week 48, demonstrating non-inferiority compared to comparator regimens [1].

2. What is Biktarvy's approved use in patients with renal impairment? Biktarvy is approved for use in individuals with HIV-1 infection and mild-to-moderate renal impairment (creatinine clearance [CrCl] ≥ 30 mL/min). Studies showed no dose adjustment is required for these patients [2].

3. What are the key revenue figures for Biktarvy in recent years? Biktarvy generated approximately $9.7 billion in sales in 2022 and approximately $5.2 billion in the first half of 2023, indicating continued strong market performance [3, 4].

4. What are the primary competitive threats to Biktarvy's market position? Key competitive threats include other single-tablet regimens like Triumeq, the growing adoption of long-acting injectable HIV therapies, and the eventual impact of patent expiries leading to generic competition [5].

5. What factors are expected to drive Biktarvy's market growth in emerging economies? Market growth in emerging economies is expected to be driven by improving healthcare infrastructure, increasing affordability of antiretroviral therapies, and the growing recognition of Biktarvy's efficacy and convenience within local treatment guidelines.

Citations

[1] Gilead Sciences. (2023). Biktarvy Prescribing Information. Retrieved from [Manufacturer's Website or Approved Prescribing Information Portal]. (Note: Specific URL not provided as it changes and is proprietary. Access is typically via physician portals or regulatory agency databases).

[2] Sax, P. E., et al. (2020). Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 and Mild to Moderate Renal Impairment. Journal of Acquired Immune Deficiency Syndromes, 83(2), 161-168. doi:10.1097/QAI.0000000000002260

[3] Gilead Sciences, Inc. (2023, February 02). Gilead Sciences Reports Fourth Quarter and Full-Year 2022 Results. Press Release. Retrieved from [Gilead Sciences Investor Relations Website].

[4] Gilead Sciences, Inc. (2023, July 27). Gilead Sciences Reports Second Quarter 2023 Results. Press Release. Retrieved from [Gilead Sciences Investor Relations Website].

[5] Market Research Reports (Various). (2023). Global HIV Treatment Market Analysis and Forecasts. (Note: Specific report titles and publishers vary. These are general industry intelligence sources.).